Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

2009152 citationsJournal Articlebronze Open Access

Authors

Egbert F. Smit · Jeroen Bosch Ziekenhuis

Sjaak A. Burgers · University of St. Gallen

Bonne Biesma · University of Sydney

Hans J.M. Smit · Vrije Universiteit Amsterdam

P Eppinga · University of Sydney

Anne‐Marie C. Dingemans · Jeroen Bosch Ziekenhuis

Markus Joerger ·

Abstract

PC as second-line treatment for relapsed NSCLC resulted in a significant 33% reduction of the hazard of disease progression as compared with pemetrexed alone.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 27, Issue 12, pp. 2038-2045

DOI: 10.1200/jco.2008.19.1650

Field-Weighted Citation Impact: 16.73